Weight-of-evidence evaluation of associations between particulate matter exposure and biomarkers of lung cancer.

Research suggests that exposure to ambient particulate matter (PM) may be associated with lung cancer; however, no mode of action (MoA) for this has been established. We applied a weight-of-evidence (WoE) approach to evaluate recent evidence from four realms of research (controlled human exposure, epidemiology, animal, and in vitro) to determine whether the overall evidence supports one or more MoAs by which PM could cause lung cancer. We evaluated three general MoAs: DNA damage and repair; other genotoxic effects, including mutagenicity and clastogenicity; and gene expression, protein expression, and DNA methylation. After assessing individual study quality, we evaluated the strength of the evidence within as well as across disciplines using a modified set of Bradford Hill considerations. We conclude that the overall WoE indicates it is plausible that PM of various size fractions may cause direct DNA damage, but the evidence is insufficient regarding the alternative MoAs we evaluated. More research is needed to determine whether DNA damage can lead to downstream events and, ultimately, lung cancer.

Lead uptake in brain capillary endothelial cells: activation by calcium store depletion.

The mechanism by which lead crosses the blood-brain barrier is not known. Brain capillary endothelial cells, which form tight junctions with each other, are an important component of the blood-brain barrier. Lead must traverse these cells to reach the brain. In the present study, uptake of lead was followed in primary cultures of bovine brain capillary endothelial cells. Lead uptake into cells was measured by monitoring the fluorescence of cells loaded with indo-1 at a wavelength where indo-1 fluorescence is independent of calcium but quenched by binding of lead. Lead uptake was visualized with digital images recorded with a fluorescence microscope. Lead added to the extracellular medium caused fluorescence quench over time which was reversed upon addition of a membrane permeant heavy metal chelator. Lead uptake by cells in suspension, measured by fluorescence spectroscopy, exhibited time and concentration dependence. Lead uptake was enhanced following depletion of intracellular Ca2+ stores by the addition of thapsigargin, cyclopiazonic acid, or tert-butylhydroquinone, inhibitors of the sarco/endoplasmic reticulum calcium ATPase. SK&F 96365, which blocks store-operated calcium channels, inhibited the stimulation of lead uptake by thapsigargin. These results indicate that indo-1 fluorescence quench is a useful method for investigation of lead uptake in brain capillary endothelial cells. Furthermore, entry of lead into these cells is activated by the depletion of intracellular Ca2+ stores and may occur via store-operated cation channels.

Cellular uptake of lead is activated by depletion of intracellular calcium stores.

The mechanisms of cellular lead uptake were characterized using a fluorescence method in cells loaded with indo-1. Pb2+ bound to intracellular indo-1 with much higher affinity than Ca2+ and quenched fluorescence at all wavelengths. Pb2+ uptake into pituitary GH3 cells, glial C6 cells, and a subclone of HEK293 cells was assessed by fluorescence quench at a Ca2+-insensitive emission wavelength. Pb2+ uptake was concentration- and time-dependent. Pb2+ uptake in all three cell types occurred at a much faster rate when intracellular Ca2+ stores were depleted by two different methods: addition of drugs that inhibit the endoplasmic reticulum Ca2+ pump (thapsigargin, cyclopiazonic acid, and tert-butylhydroquinone), and prolonged incubation of cells in Ca2+-free media. Application of receptor agonists, which deplete intracellular Ca2+ stores via inositol trisphosphate-sensitive channels, did not activate Pb2+ uptake. Agonists were just as effective as thapsigargin in stimulating uptake of Ca2+ but less so in stimulating uptake of Mn2+. Basal and stimulated Pb2+ uptake were partially reduced by 1 mM extracellular Ca2+ and strongly inhibited by 10 mM Ca2+. Pb2+ entry in GH3 cells was inhibited by two drugs that block capacitative Ca2+ entry, La3+ and SK&F 96365. Depolarization of electrically excitable GH3 cells increased the initial rate of Pb2+ uptake 1.6-fold, whereas thapsigargin increased uptake 12-fold. In conclusion, Pb2+ crosses the plasma membrane of GH3, C6, and HEK293 cells via channels that are activated by profound depletion of intracellular Ca2+ stores.

Methylmercury efflux from brain capillary endothelial cells is modulated by intracellular glutathione but not ATP.

To reach its target tissue, methylmercury must traverse brain capillary endothelial cells, the site of the blood-brain barrier. Methylmercury uptake from blood plasma into these cells is mediated in part by an amino acid carrier that transports the methylmercury-L-cysteine complex; however, the mechanism by which it is released from the endothelial cells into brain interstitial space is unknown. Using bovine brain capillary endothelial cells in culture, the present study examined the hypothesis that methylmercury is transported out of these cells as a glutathione (GSH) complex. GSH concentration in cultured bovine brain capillary endothelial cells was 13.1 +/- 3.3 nmol/mg protein. Depletion of intracellular GSH in [203Hg]methylmercury-preloaded cells by exposure to 1-chloro-2,4-dinitrobenzene or diethyl maleate decreased the rate of [203Hg]methylmercury efflux. Incubation of [203Hg]methylmercury-preloaded cells with high concentrations of S-methylglutathione, S-ethylglutathione, S-butylglutathione, and sulfobromophthalein-glutathione inhibited [203Hg]methylmercury efflux. The GSH analogs gamma-glutamylglycylglycine and ophthalmic acid also inhibited [203Hg]methylmercury efflux, but to a lesser degree than the glutathione S-conjugates, whereas L-leucine, L-methionine, and L-alanine had no effect. Efflux was not affected by depletion of intracellular ATP with 2-deoxyglucose or antimycin A. These results indicate that complexation with GSH and subsequent transport of the complex by an ATP-independent mechanism may be involved in the transport of methylmercury out of brain capillary endothelial cells.

Methylmercury-thiol uptake into cultured brain capillary endothelial cells on amino acid system L.

Recent in vivo studies suggest that the neurotoxin methylmercury (MeHg) is transported into brain as an L-cysteine complex by amino acid transport system L. To test this hypothesis, the mechanism of MeHg uptake into cultured calf brain capillary endothelial cells, an in vitro model of the blood-brain barrier, was examined. Uptake of Me203Hg-L-cysteine followed Michaelis-Menten kinetics, with a Km of 234 +/- 58 microM (mean +/- S.E.) and a Vmax of 57 +/- 25 pmol.micrograms DNA-1.15 sec-1. Uptake of 10 microM MeHg-L-cysteine was stereoselective and Na+ independent and it was inhibited by the system L substrates L-leucine, 2-amino-2-norbornanecarboxylic acid and L-methionine (5 mM), consistent with transport of MeHg-L-cysteine by the L amino acid carrier. L-Glutamate and methylaminoisobutyric acid, which are transported by the acidic and A amino acid carriers, respectively, had no effect. Moreover, uptake of 3H-L-leucine (5 microM) was inhibited by 1 mM MeHg-L-cysteine is transported into brain capillary endothelial cells by the L carrier. Uptake of other MeHg-thiols was also measured. MeHg-D, L-homocysteine uptake was 82 +/- 11% of MeHg-L-cysteine uptake, whereas uptakes of MeHg complexes of L-penicillamine, dimercaptosuccinic acid, N-acetyl-L-cysteine and glutathione were 57 +/- 16%, 19 +/- 7%, 10 +/- 4% and 8 +/- 5% of MeHg-L-cysteine uptake, respectively. These results illustrate the potential to minimize transport of MeHg across brain capillary endothelium by the careful choice of thiol complexing agent.

Methylmercury transport across the blood-brain barrier by an amino acid carrier.

The mechanism by which methylmercury (MeHg) crosses the blood-brain barrier was examined in the rat. Previous studies demonstrated that intravenous injection of L-cysteine with MeHg accelerates MeHg uptake into brain. Since the complex of MeHg with L-cysteine is structurally similar to L-methionine, a substrate for the L (leucine-preferring) amino acid transport system, this carrier may be involved in MeHg uptake. To examine this hypothesis, the rapid carotid infusion technique was used in the anesthetized rat. The concentration dependence of 203Hg uptake into brain after injection of Me203Hg-L-cysteine complex was nonlinear, exhibiting characteristics of saturable transport (apparent Michaelis constant 0.39 mM, vmax 33 nmol.min-1.g-1). A slower, nonsaturable uptake was seen after MeHg-L-cysteine uptake was inhibited by methionine and the amino acid analogue 2-aminobicyclo[2.2.1]heptane-2-carboxylic acid (BCH), an L system substrate, but not by alpha-methylaminoisobutyric acid, an alanine-preferring system substrate. Furthermore, L-[14C]methionine transport was inhibited by MeHg-L-cysteine but not by MeHgCl. There was a significant amount of uptake of 203Hg when injected as Me203Hg-glutathione, and this was inhibited by L-methionine and BCH but not D-methionine. S-ethylglutathione also inhibited 203Hg uptake after administration as Me203Hg-glutathione but had no effect on Me203Hg-L-cysteine uptake. These results suggest that MeHg may enter the brain as a cysteine complex via the L system and that plasma MeHg-glutathione serves as a source of MeHg-cysteine.